Edwin M Posadas

Title(s)HS Clinical Professor, Medicine
SchoolMedicine
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    A blood test to identify prostate cancer patients at risk for visceral metastasis
    NIH R01CA218356Jun 19, 2017 - May 31, 2022
    Role: Principal Investigator
    Thermoresponsive NanoVelcro CTC Purification System for Prostate Cancer Profiling
    NIH U01CA198900Aug 18, 2015 - Jul 31, 2021
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Progression-free survival end points in prostate cancer: are we truly making progress. Nat Rev Urol. 2024 11; 21(11):646-648. Madan RA, Posadas EM, Lee RJ. PMID: 38886519.
      View in: PubMed   Mentions: 1     Fields:    
    2. Editorial: Molecular mechanisms in lethal states of prostate cancer. Front Oncol. 2024; 14:1475178. Kim DM, Lyou Y, Ellis L, Posadas E, Bhowmick N, Gong J. PMID: 39228989; PMCID: PMC11369412.
      View in: PubMed   Mentions:
    3. Extracellular Vesicles heterogeneity through the lens of multiomics. bioRxiv. 2024 Aug 19. Silva TF, Hutchins E, Zhao W, Ciani Y, Kim M, Mariscal J, Qiu Z, Kittel A, Zhou B, Wang Y, Hall M, Galasso F, Reiman R, Freeman MR, Parker S, Van Eyk J, Yang W, Posadas E, Guarnerio J, Nolan J, Thery C, Zijlstra A, Stott S, You S, Demichelis F, Boutros P, Van Keuren-Jensen K, Di Vizio D. PMID: 39229160; PMCID: PMC11370325.
      View in: PubMed   Mentions:
    4. ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer. Nucleic Acids Res. 2024 Jul 22; 52(13):7740-7760. Qian C, Yang Q, Rotinen M, Huang R, Kim H, Gallent B, Yan Y, Cadaneanu RM, Zhang B, Kaochar S, Freedland SJ, Posadas EM, Ellis L, Di Vizio D, Morrissey C, Nelson PS, Brady L, Murali R, Campbell MJ, Yang W, Knudsen BS, Mostaghel EA, Ye H, Garraway IP, You S, Freeman MR. PMID: 38932701; PMCID: PMC11260453.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    5. Variation in content discussed by specialty in consultations for clinically localized prostate cancer. Urol Oncol. 2024 Sep; 42(9):288.e7-288.e15. Friedrich NA, Luu M, Gale R, Chaplin A, Ballas L, Sandler HM, Posadas EM, Freedland SJ, Spiegel B, Kokorowski P, Daskivich TJ. PMID: 38762384; PMCID: PMC11193607.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    6. Applications of wearable activity monitors for prostate cancer survivors: A systematic scoping review. Contemp Clin Trials. 2024 Aug; 143:107563. Raines C, Noorvash B, Posadas EM, Sandler HM, Freedland SJ, Gresham G. PMID: 38723860.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    7. Interleukin 33 supports squamous cell carcinoma growth via a dual effect on tumour proliferation, migration and invasion, and T cell activation. Cancer Immunol Immunother. 2024 Apr 25; 73(6):110. Perri G, Vilas Boas VG, Nogueira MRS, Mello Júnior EJF, Coelho AL, Posadas EM, Hogaboam C, Cavassani KA, Campanelli AP. PMID: 38662248; PMCID: PMC11045681.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    8. A practical guide for assessing and managing cardiovascular risk during androgen-deprivation therapy in patients with prostate cancer. Cancer. 2024 Jun 01; 130(11):1916-1929. Solanki AJ, Kamrava M, Posadas EM, Freedland SJ, Ballas L, Sandler HM, Bairey Merz CN, Atkins KM, Nikolova AP. PMID: 38529566.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Restaging With Prostate-Specific Membrane Antigen Imaging in Metastatic Castration-Resistant Prostate Cancer: When Seeing More Is Detrimental to Care. J Clin Oncol. 2024 Jul 01; 42(19):2242-2244. Madan RA, Yu EY, Posadas EM, Lee RJ, Karzai F, Choyke PL. PMID: 38489582.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions. J Urol. 2024 Apr; 211(4):526-532. Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. PMID: 38421252.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    11. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy. J Urol. 2024 Apr; 211(4):509-517. Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. PMID: 38421253.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    12. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy. J Urol. 2024 Apr; 211(4):518-525. Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. PMID: 38421243.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    13. Variation in communication of side effects in prostate cancer treatment consultations. Prostate Cancer Prostatic Dis. 2024 Feb 23. Daskivich TJ, Naser-Tavakolian A, Gale R, Luu M, Friedrich N, Venkataramana A, Khodyakov D, Posadas E, Sandler H, Spiegel B, Freedland SJ. PMID: 38396054; PMCID: PMC11341774.
      View in: PubMed   Mentions: 1     Fields:    
    14. Use of Persuasive Language in Communication of Risk during Prostate Cancer Treatment Consultations. Med Decis Making. 2024 04; 44(3):320-334. Naser-Tavakolian A, Gale R, Luu M, Masterson JM, Venkataramana A, Khodyakov D, Anger JT, Posadas E, Sandler H, Freedland SJ, Spiegel B, Daskivich TJ. PMID: 38347686; PMCID: PMC11102816.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. A Practical Approach for Targeting Structural Variants Genome-wide in Plasma Cell-free DNA. bioRxiv. 2024 Jan 08. Murata MM, Igari F, Urbanowicz R, Mouakkad L, Kim S, Chen Z, DiVizio D, Posadas EM, Giuliano AE, Tanaka H. PMID: 37961589; PMCID: PMC10634834.
      View in: PubMed   Mentions:
    16. A Practical Approach for Targeting Structural Variants Genome-wide in Plasma Cell-free DNA. Res Sq. 2024 Jan 05. Tanaka H, Murata M, Igari F, Urbanowicz R, Mouakkad L, Kim S, Chen Z, Di Vizio D, Posadas E, Giuliano A. PMID: 38260372; PMCID: PMC10802711.
      View in: PubMed   Mentions:
    17. Hepatic prohibitin 1 and methionine adenosyltransferase α1 defend against primary and secondary liver cancer metastasis. J Hepatol. 2024 Mar; 80(3):443-453. Fan W, Cao D, Yang B, Wang J, Li X, Kitka D, Li TWH, You S, Shiao S, Gangi A, Posadas E, Di Vizio D, Tomasi ML, Seki E, Mato JM, Yang H, Lu SC. PMID: 38086446; PMCID: PMC10922446.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    18. Genetic and biological drivers of prostate cancer disparities in Black men. Nat Rev Urol. 2024 05; 21(5):274-289. Gong J, Kim DM, Freeman MR, Kim H, Ellis L, Smith B, Theodorescu D, Posadas E, Figlin R, Bhowmick N, Freedland SJ. PMID: 37964070.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    19. Disparities With Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand? J Clin Oncol. 2024 Jan 10; 42(2):228-236. Gong J, Kim DM, De Hoedt AM, Bhowmick N, Figlin R, Kim HL, Sandler H, Theodorescu D, Posadas E, Freedland SJ. PMID: 37890125; PMCID: PMC10824384.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    20. ONECUT2 Activates Diverse Resistance Drivers of Androgen Receptor-Independent Heterogeneity in Prostate Cancer. bioRxiv. 2023 Oct 12. Qian C, Yang Q, Rotinen M, Huang R, Kim H, Gallent B, Yan Y, Cadaneanu RM, Zhang B, Kaochar S, Freedland SJ, Posadas EM, Ellis L, Vizio DD, Morrissey C, Nelson PS, Brady L, Murali R, Campbell MJ, Yang W, Knudsen BS, Mostaghel EA, Ye H, Garraway IP, You S, Freeman MR. PMID: 37905039; PMCID: PMC10614109.
      View in: PubMed   Mentions:
    21. Relative search popularity of five advanced prostate cancer medications using Google Trends. Prostate Cancer Prostatic Dis. 2024 Sep; 27(3):457-461. Das S, Friedrich NA, Daniels J, Galvan GC, Gong J, Posadas E, Aronson W, Freedland SJ. PMID: 37679603; PMCID: PMC11019934.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    22. A cisplatin conjugate with tumor cell specificity exhibits antitumor effects in renal cancer models. BMC Cancer. 2023 Jun 02; 23(1):499. Mrdenovic S, Wang Y, Yin L, Chu GC, Ou Y, Lewis MS, Heffer M, Posadas EM, Zhau HE, Chung LWK, Edderkaoui M, Pandol SJ, Wang R, Zhang Y. PMID: 37268911; PMCID: PMC10236852.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    23. Extracellular vesicles in fatty liver promote a metastatic tumor microenvironment. Cell Metab. 2023 07 11; 35(7):1209-1226.e13. Wang Z, Kim SY, Tu W, Kim J, Xu A, Yang YM, Matsuda M, Reolizo L, Tsuchiya T, Billet S, Gangi A, Noureddin M, Falk BA, Kim S, Fan W, Tighiouart M, You S, Lewis MS, Pandol SJ, Di Vizio D, Merchant A, Posadas EM, Bhowmick NA, Lu SC, Seki E. PMID: 37172577; PMCID: PMC10524732.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    24. HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma. Hepatology. 2023 03 01; 77(3):774-788. Sun N, Zhang C, Lee YT, Tran BV, Wang J, Kim H, Lee J, Zhang RY, Wang JJ, Hu J, Zhang Z, Alsudaney MS, Hou KC, Tang H, Zhang TX, Liang IY, Zhou Z, Chen M, Yeh AH, Li W, Zhou XJ, Chang HR, Han SB, Sadeghi S, Finn RS, Saab S, Busuttil RW, Noureddin M, Ayoub WS, Kuo A, Sundaram V, Al-Ghaieb B, Palomique J, Kosari K, Kim IK, Todo T, Nissen NN, Tomasi ML, You S, Posadas EM, Wu JX, Wadehra M, Sim MS, Li Y, Wang HL, French SW, Lu SC, Wu L, Pei R, Liang L, Yang JD, Agopian VG, Tseng HR, Zhu Y. PMID: 35908246; PMCID: PMC9887095.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    25. Targeting Glutamine Metabolism in Prostate Cancer. Front Biosci (Elite Ed). 2023 01 04; 15(1):2. Bhowmick N, Posadas E, Ellis L, Freedland SJ, Vizio DD, Freeman MR, Theodorescu D, Figlin R, Gong J. PMID: 36959101.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    26. Prostate cancer extracellular vesicle digital scoring assay - a rapid noninvasive approach for quantification of disease-relevant mRNAs. Nano Today. 2023 02; 48. Wang JJ, Sun N, Lee YT, Kim M, Vagner T, Rohena-Rivera K, Wang Z, Chen Z, Zhang RY, Lee J, Zhang C, Tang H, Widjaja J, Zhang TX, Qi D, Teng PC, Jan YJ, Hou KC, Hamann C, Sandler HM, Daskivich TJ, Luthringer DJ, Bhowmick NA, Pei R, You S, Di Vizio D, Tseng HR, Chen JF, Zhu Y, Posadas EM. PMID: 36711067; PMCID: PMC9879227.
      View in: PubMed   Mentions: 2  
    27. The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. Cancer Res. 2022 11 02; 82(21):3888-3902. Sjöström M, Zhao SG, Levy S, Zhang M, Ning Y, Shrestha R, Lundberg A, Herberts C, Foye A, Aggarwal R, Hua JT, Li H, Bergamaschi A, Maurice-Dror C, Maheshwari A, Chen S, Ng SWS, Ye W, Petricca J, Fraser M, Chesner L, Perry MD, Moreno-Rodriguez T, Chen WS, Alumkal JJ, Chou J, Morgans AK, Beer TM, Thomas GV, Gleave M, Lloyd P, Phillips T, McCarthy E, Haffner MC, Zoubeidi A, Annala M, Reiter RE, Rettig MB, Witte ON, Fong L, Bose R, Huang FW, Luo J, Bjartell A, Lang JM, Mahajan NP, Lara PN, Evans CP, Tran PT, Posadas EM, He C, Cui XL, Huang J, Zwart W, Gilbert LA, Maher CA, Boutros PC, Chi KN, Ashworth A, Small EJ, He HH, Wyatt AW, Quigley DA, Feng FY. PMID: 36251389; PMCID: PMC9627125.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    28. Antagonizing CD105 and androgen receptor to target stromal-epithelial interactions for clinical benefit. Mol Ther. 2023 01 04; 31(1):78-89. Smith BN, Mishra R, Billet S, Placencio-Hickok VR, Kim M, Zhang L, Duong F, Madhav A, Scher K, Moldawer N, Oppenheim A, Angara B, You S, Tighiouart M, Posadas EM, Bhowmick NA. PMID: 36045587; PMCID: PMC9840108.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    29. Intensification of Androgen Deprivation Therapy in High-Risk, Nonmetastatic Prostate Cancer: Lessons From STAMPEDE. JNCI Cancer Spectr. 2022 07 01; 6(4). Gong J, Posadas EM. PMID: 35877083; PMCID: PMC9338454.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    30. Variation in Communication of Competing Risks of Mortality in Prostate Cancer Treatment Consultations. J Urol. 2022 08; 208(2):301-308. Daskivich TJ, Gale R, Luu M, Naser-Tavakolian A, Venkataramana A, Khodyakov D, Anger JT, Posadas E, Sandler H, Spiegel B, Freedland SJ. PMID: 35377775; PMCID: PMC11070128.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    31. First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been? Drugs. 2022 Mar; 82(4):439-453. Adashek JJ, Breunig JJ, Posadas E, Bhowmick NA, Ellis L, Freedland SJ, Kim H, Figlin R, Gong J. PMID: 35175588.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    32. Circulating Fatty Objects and Their Preferential Presence in Pancreatic Cancer Patient Blood Samples. Front Physiol. 2022; 13:827531. Wang R, Nissen NN, Zhang Y, Shao C, Chu CY, Huynh C, Posadas EM, Tomlinson JS, Lewis MS, Pandol SJ. PMID: 35237181; PMCID: PMC8883044.
      View in: PubMed   Mentions: 1  
    33. Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis. Nat Commun. 2022 02 03; 13(1):669. Yan Y, Zhou B, Qian C, Vasquez A, Kamra M, Chatterjee A, Lee YJ, Yuan X, Ellis L, Di Vizio D, Posadas EM, Kyprianou N, Knudsen BS, Shah K, Murali R, Gertych A, You S, Freeman MR, Yang W. PMID: 35115556; PMCID: PMC8813925.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    34. A Humanized Monoclonal Antibody Targeting Extracellular Nicotinamide Phosphoribosyltransferase Prevents Aggressive Prostate Cancer Progression. Pharmaceuticals (Basel). 2021 Dec 17; 14(12). Sun BL, Tang L, Sun X, Garcia AN, Camp SM, Posadas E, Cress AE, Garcia JGN. PMID: 34959723; PMCID: PMC8706080.
      View in: PubMed   Mentions: 12  
    35. An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2022 06 01; 113(2):278-289. Roy S, Zaorsky NG, Bagshaw HP, Berlin A, Tree A, Turner S, Koontz B, Nguyen P, Chen R, Dess RT, Jackson WC, Kishan AU, Stish B, Nagar H, Posadas E, Tran PT, Solanki A, Shore ND, Guo G, Ponsky L, Shoag JE, Morgans AK, Garcia JA, Showalter TN, Feng FY, Spratt DE. PMID: 34923058.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    36. Discovery and characterization of circulating tumor cell clusters in neuroendocrine tumor patients using nanosubstrate-embedded microchips. Biosens Bioelectron. 2022 Mar 01; 199:113854. Sun N, Yang Y, Miao H, Redublo P, Liu H, Liu W, Huang YW, Teng PC, Zhang C, Zhang RY, Smalley M, Yang P, Chou SJ, Huai K, Zhang Z, Lee YT, Wang JJ, Wang J, Liang IY, Zhang TX, Zhang D, Liang L, Weiss PS, Posadas EM, Donahue T, Hecht JR, Allen-Auerbach MS, Bergsland EK, Hope TA, Pei R, Zhu Y, Tseng HR, Heaney AP. PMID: 34896918; PMCID: PMC8900541.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    37. miR-1227 Targets SEC23A to Regulate the Shedding of Large Extracellular Vesicles. Cancers (Basel). 2021 Nov 22; 13(22). Chin A, Mariscal J, Kim M, Guerra G, Victor B, Qian C, Broseghini E, Posadas E, Freeman MR, Sharma S, Gandellini P, Zaffaroni N, You S, Chan KS, Guarnerio J, Fabbri M, Di Vizio D. PMID: 34831007; PMCID: PMC8616086.
      View in: PubMed   Mentions: 1  
    38. Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection. Onco Targets Ther. 2021; 14:4819-4832. LeVee A, Lin CY, Posadas E, Figlin R, Bhowmick NA, Di Vizio D, Ellis L, Rosser CJ, Freeman MR, Theodorescu D, Freedland SJ, Gong J. PMID: 34552338; PMCID: PMC8450162.
      View in: PubMed   Mentions: 7  
    39. Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification. Oncology (Williston Park). 2021 09 14; 35(9):528-535. Smith B, Kim S, Tighiouart M, Posadas E, Chung L, Figlin R, Bhowmick N, Gong J. PMID: 34524771.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    40. Loss of CDCP1 triggers FAK activation in detached prostate cancer cells. Am J Clin Exp Urol. 2021; 9(4):350-366. Pollan SG, Teng PC, Jan YJ, Livingstone J, Huang C, Kim M, Mariscal J, Rodriguez M, Chen JF, You S, DiVizio D, Boutros PC, Chan KS, Rasorenova O, Cress A, Spassov D, Moasser M, Posadas EM, Freedland SJ, Freeman MR, Zheng JJ, Knudsen BS. PMID: 34541033; PMCID: PMC8446766.
      View in: PubMed   Mentions: 3  
    41. Scaffold attachment factor B1 regulates androgen degradation pathways in prostate cancer. Am J Clin Exp Urol. 2021; 9(4):337-349. Yang JS, Qian C, You S, Rotinen M, Posadas EM, Freedland SJ, Di Vizio D, Kim J, Freeman MR. PMID: 34541032; PMCID: PMC8446770.
      View in: PubMed   Mentions: 2  
    42. Covalent Chemistry-Mediated Multimarker Purification of Circulating Tumor Cells Enables Noninvasive Detection of Molecular Signatures of Hepatocellular Carcinoma. Adv Mater Technol. 2021 May; 6(5). Sun N, Lee YT, Kim M, Wang JJ, Zhang C, Teng PC, Qi D, Zhang RY, Tran BV, Lee YT, Ye J, Palomique J, Nissen NN, Han SB, Sadeghi S, Finn RS, Saab S, Busuttil RW, Posadas EM, Liang L, Pei R, Yang JD, You S, Agopian VG, Tseng HR, Zhu Y. PMID: 34212072; PMCID: PMC8240468.
      View in: PubMed   Mentions: 2  
    43. Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE). Cancer Chemother Pharmacol. 2021 07; 88(1):25-37. Saad F, Chi KN, Shore ND, Graff JN, Posadas EM, Lattouf JB, Espina BM, Zhu E, Yu A, Hazra A, De Meulder M, Mamidi RNVS, Bradic B, Francis P, Hayreh V, Rezazadeh Kalebasty A. PMID: 33754187; PMCID: PMC8149334.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    44. Disparities in Cancer Care and the Asian American Population. Oncologist. 2021 06; 26(6):453-460. Lee RJ, Madan RA, Kim J, Posadas EM, Yu EY. PMID: 33683795; PMCID: PMC8176990.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    45. Correction: A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2). Clin Cancer Res. 2021 Mar 15; 27(6):1823. Freedland SJ, Allen J, Jarman A, Oyekunle T, Armstrong AJ, Moul JW, Sandler HM, Posadas E, Levin D, Wiggins E, Howard LE, Wu Y, Lin PH. PMID: 33712498.
      View in: PubMed   Mentions:    Fields:    
    46. Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics. Oncology (Williston Park). 2021 Mar 15; 35(3):119-125. Gong J, Posadas E, Bhowmick N, Kim H, Daskivich T, Gupta A, Sandler H, Kamrava M, Zumsteg Z, Freedland S, Figlin R. PMID: 33818052.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    47. A comparative study of PCS and PAM50 prostate cancer classification schemes. Prostate Cancer Prostatic Dis. 2021 09; 24(3):733-742. Yoon J, Kim M, Posadas EM, Freedland SJ, Liu Y, Davicioni E, Den RB, Trock BJ, Karnes RJ, Klein EA, Freeman MR, You S. PMID: 33531653; PMCID: PMC8326303.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    48. Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma. Hepatology. 2021 01; 73(1):422-436. Ahn JC, Teng PC, Chen PJ, Posadas E, Tseng HR, Lu SC, Yang JD. PMID: 32017145; PMCID: PMC8183673.
      View in: PubMed   Mentions: 146     Fields:    Translation:HumansCells
    49. Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer. Clin Cancer Res. 2021 03 15; 27(6):1623-1630. Marshall CH, Fu W, Wang H, Park JC, DeWeese TL, Tran PT, Song DY, King S, Afful M, Hurrelbrink J, Manogue C, Cotogno P, Moldawer NP, Barata PC, Drake CG, Posadas EM, Armstrong AJ, Sartor O, Antonarakis ES. PMID: 33451978; PMCID: PMC8121020.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    50. Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer. Eur Urol. 2021 06; 79(6):762-771. Casanova-Salas I, Athie A, Boutros PC, Del Re M, Miyamoto DT, Pienta KJ, Posadas EM, Sowalsky AG, Stenzl A, Wyatt AW, Mateo J. PMID: 33422353; PMCID: PMC8941682.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCells
    51. Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring. Nat Commun. 2020 09 07; 11(1):4489. Sun N, Lee YT, Zhang RY, Kao R, Teng PC, Yang Y, Yang P, Wang JJ, Smalley M, Chen PJ, Kim M, Chou SJ, Bao L, Wang J, Zhang X, Qi D, Palomique J, Nissen N, Han SB, Sadeghi S, Finn RS, Saab S, Busuttil RW, Markovic D, Elashoff D, Yu HH, Li H, Heaney AP, Posadas E, You S, Yang JD, Pei R, Agopian VG, Tseng HR, Zhu Y. PMID: 32895384; PMCID: PMC7477161.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansCells
    52. COVID-19 and androgen-targeted therapy for prostate cancer patients. Endocr Relat Cancer. 2020 09; 27(9):R281-R292. Bhowmick NA, Oft J, Dorff T, Pal S, Agarwal N, Figlin RA, Posadas EM, Freedland SJ, Gong J. PMID: 32508311; PMCID: PMC7546583.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCellsPHPublic Health
    53. Combination Androgen Receptor Inhibition and Docetaxel in Metastatic Castration-sensitive Prostate Cancer: The Next Step in First-line Treatment? Clin Genitourin Cancer. 2020 12; 18(6):425-428. Adashek JJ, Reed JP, Tandon A, Freedland SJ, Posadas E, Bhowmick N, Chung LW, Freeman M, Figlin RA, Gong J. PMID: 32631766; PMCID: PMC9212901.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    54. Evaluating Changes in Immune Function and Bone Microenvironment During Radium-223 Treatment of Patients with Castration-Resistant Prostate Cancer. Cancer Biother Radiopharm. 2020 Sep; 35(7):485-489. Dorff TB, Stein C, Kortylewski M, Posadas E, Synold T, Quinn D. PMID: 32366119.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    55. Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study. Clin Cancer Res. 2020 07 15; 26(14):3517-3524. Posadas EM, Chi KN, de Wit R, de Jonge MJA, Attard G, Friedlander TW, Yu MK, Hellemans P, Chien C, Abrams C, Jiao JJ, Saad F. PMID: 32366670.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    56. Cancer epithelia-derived mitochondrial DNA is a targetable initiator of a paracrine signaling loop that confers taxane resistance. Proc Natl Acad Sci U S A. 2020 04 14; 117(15):8515-8523. Haldar S, Mishra R, Billet S, Thiruvalluvan M, Placencio-Hickok VR, Madhav A, Duong F, Angara B, Agarwal P, Tighiouart M, Posadas EM, Bhowmick NA. PMID: 32238563; PMCID: PMC7165425.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    57. Loss of testosterone impairs anti-tumor neutrophil function. Nat Commun. 2020 03 31; 11(1):1613. Markman JL, Porritt RA, Wakita D, Lane ME, Martinon D, Noval Rivas M, Luu M, Posadas EM, Crother TR, Arditi M. PMID: 32235862; PMCID: PMC7109066.
      View in: PubMed   Mentions: 28     Fields:    Translation:AnimalsCells
    58. A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2). Clin Cancer Res. 2020 06 15; 26(12):3035-3043. Freedland SJ, Allen J, Jarman A, Oyekunle T, Armstrong AJ, Moul JW, Sandler HM, Posadas E, Levin D, Wiggins E, Howard LE, Wu Y, Lin PH. PMID: 32108029.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    59. Covalent chemistry on nanostructured substrates enables noninvasive quantification of gene rearrangements in circulating tumor cells. Sci Adv. 2019 07; 5(7):eaav9186. Dong J, Jan YJ, Cheng J, Zhang RY, Meng M, Smalley M, Chen PJ, Tang X, Tseng P, Bao L, Huang TY, Zhou D, Liu Y, Chai X, Zhang H, Zhou A, Agopian VG, Posadas EM, Shyue JJ, Jonas SJ, Weiss PS, Li M, Zheng G, Yu HH, Zhao M, Tseng HR, Zhu Y. PMID: 31392269; PMCID: PMC6669017.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    60. Brain Metastases in Renal Cell Carcinoma: Immunotherapy Responsiveness Is Multifactorial and Heterogeneous. J Clin Oncol. 2019 08 10; 37(23):1987-1989. Reed JP, Posadas EM, Figlin RA. PMID: 31232668.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    61. A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. Theranostics. 2019; 9(10):2812-2826. Jan YJ, Yoon J, Chen JF, Teng PC, Yao N, Cheng S, Lozano A, Chu GCY, Chung H, Lu YT, Chen PJ, Wang JJ, Lee YT, Kim M, Zhu Y, Knudsen BS, Feng FY, Garraway IP, Gao AC, Chung LWK, Freeman MR, You S, Tseng HR, Posadas EM. PMID: 31244925; PMCID: PMC6568173.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    62. Bio-Inspired NanoVilli Chips for Enhanced Capture of Tumor-Derived Extracellular Vesicles: Toward Non-Invasive Detection of Gene Alterations in Non-Small Cell Lung Cancer. ACS Appl Mater Interfaces. 2019 Apr 17; 11(15):13973-13983. Dong J, Zhang RY, Sun N, Smalley M, Wu Z, Zhou A, Chou SJ, Jan YJ, Yang P, Bao L, Qi D, Tang X, Tseng P, Hua Y, Xu D, Kao R, Meng M, Zheng X, Liu Y, Vagner T, Chai X, Zhou D, Li M, Chiou SH, Zheng G, Di Vizio D, Agopian VG, Posadas E, Jonas SJ, Ju SP, Weiss PS, Zhao M, Tseng HR, Zhu Y. PMID: 30892008; PMCID: PMC6545291.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    63. Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell Carcinoma. Case Rep Urol. 2019; 2019:6769017. Uche A, Sila C, Tanoura T, Yeh J, Bhowmick N, Posadas E, Figlin R, Gong J. PMID: 30906615; PMCID: PMC6393887.
      View in: PubMed   Mentions: 10  
    64. Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma. Expert Rev Anticancer Ther. 2019 03; 19(3):259-271. Reed JP, Posadas EM, Figlin RA. PMID: 30669895.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    65. Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma. Clin Genitourin Cancer. 2019 06; 17(3):e454-e460. Adashek JJ, Salgia MM, Posadas EM, Figlin RA, Gong J. PMID: 30733185.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    66. Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. Clin Cancer Res. 2019 04 15; 25(8):2450-2457. Zhao SG, Chen WS, Das R, Chang SL, Tomlins SA, Chou J, Quigley DA, Dang HX, Barnard TJ, Mahal BA, Gibb EA, Liu Y, Davicioni E, Duska LR, Posadas EM, Jolly S, Spratt DE, Nguyen PL, Maher CA, Small EJ, Feng FY. PMID: 30573691.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    67. Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2018 10 01; 4(10):1344-1351. Autio KA, Dreicer R, Anderson J, Garcia JA, Alva A, Hart LL, Milowsky MI, Posadas EM, Ryan CJ, Graf RP, Dittamore R, Schreiber NA, Summa JM, Youssoufian H, Morris MJ, Scher HI. PMID: 29978216; PMCID: PMC6233779.
      View in: PubMed   Mentions: 85     Fields:    Translation:HumansCTClinical Trials
    68. An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma. Oncologist. 2019 02; 24(2):202-210. Choueiri TK, Michaelson MD, Posadas EM, Sonpavde GP, McDermott DF, Nixon AB, Liu Y, Yuan Z, Seon BK, Walsh M, Jivani MA, Adams BJ, Theuer CP. PMID: 30190302; PMCID: PMC6369938.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    69. Emerin Deregulation Links Nuclear Shape Instability to Metastatic Potential. Cancer Res. 2018 11 01; 78(21):6086-6097. Reis-Sobreiro M, Chen JF, Novitskaya T, You S, Morley S, Steadman K, Gill NK, Eskaros A, Rotinen M, Chu CY, Chung LWK, Tanaka H, Yang W, Knudsen BS, Tseng HR, Rowat AC, Posadas EM, Zijlstra A, Di Vizio D, Freeman MR. PMID: 30154147.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimalsCells
    70. Circulating monocytes from prostate cancer patients promote invasion and motility of epithelial cells. Cancer Med. 2018 09; 7(9):4639-4649. Cavassani KA, Meza RJ, Habiel DM, Chen JF, Montes A, Tripathi M, Martins GA, Crother TR, You S, Hogaboam CM, Bhowmick N, Posadas EM. PMID: 30094958; PMCID: PMC6143932.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    71. Large extracellular vesicles carry most of the tumour DNA circulating in prostate cancer patient plasma. J Extracell Vesicles. 2018; 7(1):1505403. Vagner T, Spinelli C, Minciacchi VR, Balaj L, Zandian M, Conley A, Zijlstra A, Freeman MR, Demichelis F, De S, Posadas EM, Tanaka H, Di Vizio D. PMID: 30108686; PMCID: PMC6084494.
      View in: PubMed   Mentions: 206     Fields:    
    72. Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming. J Clin Invest. 2018 10 01; 128(10):4472-4484. Mishra R, Haldar S, Placencio V, Madhav A, Rohena-Rivera K, Agarwal P, Duong F, Angara B, Tripathi M, Liu Z, Gottlieb RA, Wagner S, Posadas EM, Bhowmick NA. PMID: 30047926; PMCID: PMC6159981.
      View in: PubMed   Mentions: 75     Fields:    Translation:HumansAnimalsCells
    73. Structure and function analysis in circulating tumor cells: using nanotechnology to study nuclear size in prostate cancer. Am J Clin Exp Urol. 2018; 6(2):43-54. Yao N, Jan YJ, Cheng S, Chen JF, Chung LW, Tseng HR, Posadas EM. PMID: 29666832; PMCID: PMC5902722.
      View in: PubMed   Mentions: 3  
    74. Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate. J Med Chem. 2018 03 08; 61(5):2052-2061. Salem AF, Wang S, Billet S, Chen JF, Udompholkul P, Gambini L, Baggio C, Tseng HR, Posadas EM, Bhowmick NA, Pellecchia M. PMID: 29470068; PMCID: PMC5907794.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    75. NanoVelcro rare-cell assays for detection and characterization of circulating tumor cells. Adv Drug Deliv Rev. 2018 02 01; 125:78-93. Jan YJ, Chen JF, Zhu Y, Lu YT, Chen SH, Chung H, Smalley M, Huang YW, Dong J, Chen LC, Yu HH, Tomlinson JS, Hou S, Agopian VG, Posadas EM, Tseng HR. PMID: 29551650; PMCID: PMC5993593.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    76. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncol. 2017 12 01; 3(12):1663-1672. Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, Speers C, Cooperberg MR, Kim W, Ryan CJ, Den RB, Freedland SJ, Posadas E, Sandler H, Klein EA, Black P, Seiler R, Tomlins SA, Chinnaiyan AM, Jenkins RB, Davicioni E, Ross AE, Schaeffer EM, Nguyen PL, Carroll PR, Karnes RJ, Spratt DE, Feng FY. PMID: 28494073; PMCID: PMC5824281.
      View in: PubMed   Mentions: 142     Fields:    Translation:Humans
    77. Modulation of cabozantinib efficacy by the prostate tumor microenvironment. Oncotarget. 2017 Oct 20; 8(50):87891-87902. Tripathi M, Nandana S, Billet S, Cavassani KA, Mishra R, Chung LWK, Posadas EM, Bhowmick NA. PMID: 29152128; PMCID: PMC5675680.
      View in: PubMed   Mentions: 10     Fields:    
    78. Glycan Stimulation Enables Purification of Prostate Cancer Circulating Tumor Cells on PEDOT NanoVelcro Chips for RNA Biomarker Detection. Adv Healthc Mater. 2018 02; 7(3). Shen MY, Chen JF, Luo CH, Lee S, Li CH, Yang YL, Tsai YH, Ho BC, Bao LR, Lee TJ, Jan YJ, Zhu YZ, Cheng S, Feng FY, Chen P, Hou S, Agopian V, Hsiao YS, Tseng HR, Posadas EM, Yu HH. PMID: 28892262; PMCID: PMC5803304.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    79. S-adenosylmethionine and methylthioadenosine inhibit cancer metastasis by targeting microRNA 34a/b-methionine adenosyltransferase 2A/2B axis. Oncotarget. 2017 Oct 03; 8(45):78851-78869. Tomasi ML, Cossu C, Spissu Y, Floris A, Ryoo M, Iglesias-Ara A, Wang Q, Pandol SJ, Bhowmick NA, Seki E, Posadas EM, Lu SC. PMID: 29108270; PMCID: PMC5668003.
      View in: PubMed   Mentions: 19     Fields:    
    80. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol. 2018 02; 73(2):156-165. Spratt DE, Dess RT, Zumsteg ZS, Lin DW, Tran PT, Morgan TM, Antonarakis ES, Nguyen PL, Ryan CJ, Sandler HM, Cooperberg MR, Posadas E, Feng FY. PMID: 28716370.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    81. Targeted therapies for renal cell carcinoma. Nat Rev Nephrol. 2017 Aug; 13(8):496-511. Posadas EM, Limvorasak S, Figlin RA. PMID: 28691713.
      View in: PubMed   Mentions: 121     Fields:    Translation:Humans
    82. MAOA-Dependent Activation of Shh-IL6-RANKL Signaling Network Promotes Prostate Cancer Metastasis by Engaging Tumor-Stromal Cell Interactions. Cancer Cell. 2017 03 13; 31(3):368-382. Wu JB, Yin L, Shi C, Li Q, Duan P, Huang JM, Liu C, Wang F, Lewis M, Wang Y, Lin TP, Pan CC, Posadas EM, Zhau HE, Chung LWK. PMID: 28292438.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansAnimalsCells
    83. MYC Mediates Large Oncosome-Induced Fibroblast Reprogramming in Prostate Cancer. Cancer Res. 2017 05 01; 77(9):2306-2317. Minciacchi VR, Spinelli C, Reis-Sobreiro M, Cavallini L, You S, Zandian M, Li X, Mishra R, Chiarugi P, Adam RM, Posadas EM, Viglietto G, Freeman MR, Cocucci E, Bhowmick NA, Di Vizio D. PMID: 28202510.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansAnimalsCells
    84. Circulating tumor cells in prostate cancer: beyond enumeration. Clin Adv Hematol Oncol. 2017 Jan; 15(1):63-73. Chen JF, Lu YT, Cheng S, Tseng HR, Figlin RA, Posadas EM. PMID: 28212371.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    85. Recent Advances in the Medical Treatment of Recurrent or Metastatic Renal Cell Cancer. Drugs. 2017 Jan; 77(1):17-28. Kumbla RA, Figlin RA, Posadas EM. PMID: 27995579.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    86. Biology and therapy of urological cancer metastasis. Asian J Urol. 2016 Oct; 3(4):167-169. Posadas EM, McConkey DJ, Chung LWK. PMID: 29264185; PMCID: PMC5730865.
      View in: PubMed   Mentions:
    87. Third-Line Treatment Options for Kidney Cancer. Oncology (Williston Park). 2016 09 15; 30(9):813-5. Posadas EM, Limvorasak S, Figlin RA. PMID: 27633411.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    88. Applications of circulating tumor cells for prostate cancer. Asian J Urol. 2016 Oct; 3(4):254-259. Cheng S, Chen JF, Lu YT, Chung LWK, Tseng HR, Posadas EM. PMID: 29264193; PMCID: PMC5730870.
      View in: PubMed   Mentions: 1  
    89. In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database. Eur Urol Focus. 2017 10; 3(4-5):480-486. Whitney CA, Howard LE, Posadas EM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ. PMID: 28753787.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    90. Cultured circulating tumor cells and their derived xenografts for personalized oncology. Asian J Urol. 2016 Oct; 3(4):240-253. Wang R, Chu GCY, Mrdenovic S, Annamalai AA, Hendifar AE, Nissen NN, Tomlinson JS, Lewis M, Palanisamy N, Tseng HR, Posadas EM, Freeman MR, Pandol SJ, Zhau HE, Chung LWK. PMID: 29264192; PMCID: PMC5730836.
      View in: PubMed   Mentions: 21  
    91. Clinical Applications of NanoVelcro Rare-Cell Assays for Detection and Characterization of Circulating Tumor Cells. Theranostics. 2016; 6(9):1425-39. Chen JF, Zhu Y, Lu YT, Hodara E, Hou S, Agopian VG, Tomlinson JS, Posadas EM, Tseng HR. PMID: 27375790; PMCID: PMC4924510.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimalsCells
    92. Personalized Therapeutics and Value in Renal Cell Carcinoma: Moving Beyond Lines of Therapy. J Oncol Pract. 2016 05; 12(5):424-5. Posadas EM, Figlin RA. PMID: 27170689.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    93. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2016 11; 70(5):718-721. Tagawa ST, Posadas EM, Bruce J, Lim EA, Petrylak DP, Peng W, Kheoh T, Maul S, Smit JW, Gonzalez MD, De Porre P, Tran N, Nanus DM. PMID: 26852075.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    94. SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer. Oncotarget. 2015 Dec 29; 6(42):44072-83. Gururajan M, Cavassani KA, Sievert M, Duan P, Lichterman J, Huang JM, Smith B, You S, Nandana S, Chu GC, Mink S, Josson S, Liu C, Morello M, Jones LW, Kim J, Freeman MR, Bhowmick N, Zhau HE, Chung LW, Posadas EM. PMID: 26624980; PMCID: PMC4792542.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    95. A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer. Oncotarget. 2015 Dec 29; 6(42):44781-93. Jiang R, Lu YT, Ho H, Li B, Chen JF, Lin M, Li F, Wu K, Wu H, Lichterman J, Wan H, Lu CL, OuYang W, Ni M, Wang L, Li G, Lee T, Zhang X, Yang J, Rettig M, Chung LW, Yang H, Li KC, Hou Y, Tseng HR, Hou S, Xu X, Wang J, Posadas EM. PMID: 26575023; PMCID: PMC4792591.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCells
    96. Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study. Prostate. 2016 Feb 15; 76(3):286-93. Posadas EM, Ahmed RS, Karrison T, Szmulewitz RZ, O'Donnell PH, Wade JL, Shen J, Gururajan M, Sievert M, Stadler WM. PMID: 26493492; PMCID: PMC4904773.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    97. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database. Cancer. 2016 Jan 15; 122(2):222-9. Hanyok BT, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Posadas EM, Freedland SJ. PMID: 26484853.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    98. Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. Urol Oncol. 2016 Jan; 34(1):4.e11-7. Hahn NM, Knudsen BS, Daneshmand S, Koch MO, Bihrle R, Foster RS, Gardner TA, Cheng L, Liu Z, Breen T, Fleming MT, Lance R, Corless CL, Alva AS, Shen SS, Huang F, Gertych A, Gallick GE, Mallick J, Ryan C, Galsky MD, Lerner SP, Posadas EM, Sonpavde G. PMID: 26362343.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    99. Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases. Cancer. 2015 Sep 15; 121(18):3240-51. Chen JF, Ho H, Lichterman J, Lu YT, Zhang Y, Garcia MA, Chen SF, Liang AJ, Hodara E, Zhau HE, Hou S, Ahmed RS, Luthringer DJ, Huang J, Li KC, Chung LW, Ke Z, Tseng HR, Posadas EM. PMID: 25975562; PMCID: PMC4560974.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCells
    100. miR-154* and miR-379 in the DLK1-DIO3 microRNA mega-cluster regulate epithelial to mesenchymal transition and bone metastasis of prostate cancer. Clin Cancer Res. 2014 Dec 15; 20(24):6559-69. Gururajan M, Josson S, Chu GC, Lu CL, Lu YT, Haga CL, Zhau HE, Liu C, Lichterman J, Duan P, Posadas EM, Chung LW. PMID: 25324143; PMCID: PMC4710473.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansAnimalsCells
    101. miR-409-3p/-5p promotes tumorigenesis, epithelial-to-mesenchymal transition, and bone metastasis of human prostate cancer. Clin Cancer Res. 2014 Sep 01; 20(17):4636-46. Josson S, Gururajan M, Hu P, Shao C, Chu GY, Zhau HE, Liu C, Lao K, Lu CL, Lu YT, Lichterman J, Nandana S, Li Q, Rogatko A, Berel D, Posadas EM, Fazli L, Sareen D, Chung LW. PMID: 24963047; PMCID: PMC4155061.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansAnimalsCells
    102. Kidney cancer: progress and controversies in neoadjuvant therapy. Nat Rev Urol. 2014 May; 11(5):254-5. Posadas EM, Figlin RA. PMID: 24752207.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    103. Detection of live circulating tumor cells by a class of near-infrared heptamethine carbocyanine dyes in patients with localized and metastatic prostate cancer. PLoS One. 2014; 9(2):e88967. Shao C, Liao CP, Hu P, Chu CY, Zhang L, Bui MH, Ng CS, Josephson DY, Knudsen B, Tighiouart M, Kim HL, Zhau HE, Chung LW, Wang R, Posadas EM. PMID: 24551200; PMCID: PMC3925210.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    104. Large oncosomes mediate intercellular transfer of functional microRNA. Cell Cycle. 2013 Nov 15; 12(22):3526-36. Morello M, Minciacchi VR, de Candia P, Yang J, Posadas E, Kim H, Griffiths D, Bhowmick N, Chung LW, Gandellini P, Freeman MR, Demichelis F, Di Vizio D. PMID: 24091630; PMCID: PMC3906338.
      View in: PubMed   Mentions: 122     Fields:    Translation:HumansCells
    105. Targeting angiogenesis in renal cell carcinoma. Expert Opin Pharmacother. 2013 Nov; 14(16):2221-36. Posadas EM, Limvorasak S, Sharma S, Figlin RA. PMID: 23984807.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    106. NanoVelcro Chip for CTC enumeration in prostate cancer patients. Methods. 2013 Dec 01; 64(2):144-52. Lu YT, Zhao L, Shen Q, Garcia MA, Wu D, Hou S, Song M, Xu X, Ouyang WH, Ouyang WW, Lichterman J, Luo Z, Xuan X, Huang J, Chung LW, Rettig M, Tseng HR, Shao C, Posadas EM. PMID: 23816790; PMCID: PMC3834112.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansCells
    107. High-purity prostate circulating tumor cell isolation by a polymer nanofiber-embedded microchip for whole exome sequencing. Adv Mater. 2013 Jun 04; 25(21):2897-902. Zhao L, Lu YT, Li F, Wu K, Hou S, Yu J, Shen Q, Wu D, Song M, OuYang WH, Luo Z, Lee T, Fang X, Shao C, Xu X, Garcia MA, Chung LW, Rettig M, Tseng HR, Posadas EM. PMID: 23529932; PMCID: PMC3875622.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCells
    108. A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2013 Apr; 71(4):883-92. Antonarakis ES, Heath EI, Posadas EM, Yu EY, Harrison MR, Bruce JY, Cho SY, Wilding GE, Fetterly GJ, Hangauer DG, Kwan MF, Dyster LM, Carducci MA. PMID: 23314737; PMCID: PMC3609871.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCellsCTClinical Trials
    109. Understanding the role of MET kinase in cancer therapy. J Clin Oncol. 2013 Jan 10; 31(2):169-70. Posadas EM, Figlin RA. PMID: 23213104.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    110. Systemic therapy in renal cell carcinoma: advancing paradigms. Oncology (Williston Park). 2012 Mar; 26(3):290-301. Posadas EM, Figlin RA. PMID: 22545314.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    111. Future perspectives of prostate cancer therapy. Transl Androl Urol. 2012 Jan 03; 1(1):19-32. Gururajan M, Posadas EM, Chung LW. PMID: 22773967; PMCID: PMC3389805.
      View in: PubMed   Mentions: 11  
    112. Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer. 2011 Dec; 47(18):2706-14. Tannir NM, Wong YN, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, Posadas EM, Cho D, Choueiri TK, Coates A, Gupta N, Pradhan R, Qian J, Chen J, Scappaticci FA, Ricker JL, Carlson DM, Michaelson MD. PMID: 22078932; PMCID: PMC4167844.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    113. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer. 2012 Jan 01; 118(1):63-71. Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal S, Logothetis CJ. PMID: 21976132; PMCID: PMC3898168.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansCTClinical Trials
    114. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology. 2011 May; 77(5):1166-71. Yu EY, Massard C, Gross ME, Carducci MA, Culine S, Hudes G, Posadas EM, Sternberg CN, Wilding G, Trudel GC, Paliwal P, Fizazi K. PMID: 21539969; PMCID: PMC3394099.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    115. Individualized decision-making for older men with prostate cancer: balancing cancer control with treatment consequences across the clinical spectrum. Semin Oncol. 2011 Apr; 38(2):309-25. Sajid S, Mohile SG, Szmulewitz R, Posadas E, Dale W. PMID: 21421119.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    116. A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma. Am J Clin Oncol. 2011 Apr; 34(2):150-4. Chung EK, Posadas EM, Kasza K, Karrison T, Manchen E, Hahn OM, Stadler WM. PMID: 20395787; PMCID: PMC4644601.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    117. Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells. Clin Cancer Res. 2011 May 15; 17(10):3112-22. Jensen AR, David SY, Liao C, Dai J, Keller ET, Al-Ahmadie H, Dakin-Haché K, Usatyuk P, Sievert MF, Paner GP, Yala S, Cervantes GM, Natarajan V, Salgia R, Posadas EM. PMID: 21364031; PMCID: PMC3118405.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    118. Editorial comment. Urology. 2011 Jan; 77(1):165-6. O'Donnell PH, Posadas EM. PMID: 21195839.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    119. Fyn: a novel molecular target in cancer. Cancer. 2010 Apr 01; 116(7):1629-37. Saito YD, Jensen AR, Salgia R, Posadas EM. PMID: 20151426; PMCID: PMC2847065.
      View in: PubMed   Mentions: 112     Fields:    Translation:HumansCells
    120. Renal medullary-like carcinoma in an adult without sickle cell hemoglobinopathy. Nat Rev Urol. 2010 Feb; 7(2):110-4. O'Donnell PH, Jensen A, Posadas EM, Bridge JA, Yeldandi AV, Yang XJ, Stadler WM, Al-Ahmadie H. PMID: 20145663.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    121. Kinase inhibitors in prostate cancer. Anticancer Agents Med Chem. 2009 Dec; 9(10):1089-104. Limvorasak S, Posadas EM. PMID: 19925393.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    122. Pazopanib: therapeutic developments. Expert Opin Pharmacother. 2009 Dec; 10(18):3091-102. Limvorasak S, Posadas EM. PMID: 19954277.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    123. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2009 Dec 01; 15(23):7421-8. Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, Morris MJ, Hudes G, Calabrò F, Cheng S, Trudel GC, Paliwal P, Sternberg CN. PMID: 19920114; PMCID: PMC3394097.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansCTClinical Trials
    124. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs. 2009 Mar; 20(3):179-84. Lara PN, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G, Posadas E, Stadler W, Gandara DR. PMID: 19396016; PMCID: PMC3225398.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCTClinical Trials
    125. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol. 2009 Jul; 56(1):97-103. Szmulewitz R, Mohile S, Posadas E, Kunnavakkam R, Karrison T, Manchen E, Stadler WM. PMID: 19282098; PMCID: PMC2885777.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    126. Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma. Clin Genitourin Cancer. 2009 Jan; 7(1):39-42. Bylow KA, Atkins MB, Posadas EM, Stadler WM, McDermott DF. PMID: 19213667.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    127. FYN is overexpressed in human prostate cancer. BJU Int. 2009 Jan; 103(2):171-7. Posadas EM, Al-Ahmadie H, Robinson VL, Jagadeeswaran R, Otto K, Kasza KE, Tretiakov M, Siddiqui J, Pienta KJ, Stadler WM, Rinker-Schaeffer C, Salgia R. PMID: 18990162; PMCID: PMC2741693.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCells
    128. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol. 2008 Aug 01; 26(22):3709-14. Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, Chow C, Chen HX, Wright JJ, Figg WD, Kohn EC. PMID: 18669456; PMCID: PMC9089757.
      View in: PubMed   Mentions: 125     Fields:    Translation:HumansCTClinical Trials
    129. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res. 2008 Jan 01; 14(1):209-14. Dahut WL, Scripture C, Posadas E, Jain L, Gulley JL, Arlen PM, Wright JJ, Yu Y, Cao L, Steinberg SM, Aragon-Ching JB, Venitz J, Jones E, Chen CC, Figg WD. PMID: 18172272.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansCTClinical Trials
    130. A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer. 2007 Jul 15; 110(2):309-17. Posadas EM, Kwitkowski V, Kotz HL, Espina V, Minasian L, Tchabo N, Premkumar A, Hussain MM, Chang R, Steinberg SM, Kohn EC. PMID: 17559139.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    131. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer. 2007 Apr 01; 109(7):1323-30. Posadas EM, Liel MS, Kwitkowski V, Minasian L, Godwin AK, Hussain MM, Espina V, Wood BJ, Steinberg SM, Kohn EC. PMID: 17330838; PMCID: PMC2778218.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCellsCTClinical Trials
    132. A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma. Cancer Biol Ther. 2007 Apr; 6(4):490-3. Posadas EM, Undevia S, Manchen E, Wade JL, Colevas AD, Karrison T, Vokes EE, Stadler WM. PMID: 17457044.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    133. A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther. 2005 Oct; 4(10):1133-7. Posadas EM, Gulley J, Arlen PM, Trout A, Parnes HL, Wright J, Lee MJ, Chung EJ, Trepel JB, Sparreboom A, Chen C, Jones E, Steinberg SM, Daniels A, Figg WD, Dahut WL. PMID: 16138006.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    134. Management of patients with metastatic cancer of unknown primary. Curr Probl Surg. 2005 Jan; 42(1):12-66. Ghosh L, Dahut W, Kakar S, Posadas EM, Torres CG, Cancel-Santiago R, Ghosh BC. PMID: 15711508.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    135. Non-Hodgkin's lymphoma in Job's syndrome: a case report and literature review. Leuk Lymphoma. 2004 Dec; 45(12):2521-5. Leonard GD, Posadas E, Herrmann PC, Anderson VL, Jaffe ES, Holland SM, Wilson WH. PMID: 15621772.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    136. Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature. Curr Opin Oncol. 2004 Sep; 16(5):478-84. Posadas EM, Davidson B, Kohn EC. PMID: 15314519.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    137. The emerging role of bisphosphonates in prostate cancer. Am J Ther. 2004 Jan-Feb; 11(1):60-73. Posadas EM, Dahut WL, Gulley J. PMID: 14704597.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    138. Approaches to inhibit invasiveness and metastasis in prostate cancer. Clin Prostate Cancer. 2002 Sep; 1(2):125. Posadas EM, Dahut WL. PMID: 15046704.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    Edwin's Networks
    Concepts (434)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (78)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California